-
1 Comment
Samil Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 7.3% below its 200 day moving average.
From a valuation standpoint, the stock is 88.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Samil Pharmaceutical Co.,Ltd's total revenue sank by 0.4% to $30B since the same quarter in the previous year.
Its net income has increased by 42.4% to $-545M since the same quarter in the previous year.
Finally, its free cash flow fell by 146.9% to $-4B since the same quarter in the previous year.
Based on the above factors, Samil Pharmaceutical Co.,Ltd gets an overall score of 2/5.
| Exchange | KO |
|---|---|
| CurrencyCode | KRW |
| ISIN | KR7000520007 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.41 |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Market Cap | 273B |
| Dividend Yield | None |
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 000520.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
